SITUATION OF RHEUMATOID ARTHRITIS PATIENTS TREATED WITH BIOLOGICS IN GERMANY BASED ON A CLAIMS DATA ANALYSIS

被引：0
|
作者：
Walzer, S. [1 ]
Schleich, W. [1 ]
Rex, J. [2 ]
Vollmer, L. [1 ]
机构：
[1] MArS Market Access & Pricing Strategy GmbH, Weil Am Rhein, Germany
[2] Elsevier Hlth Analyt, Berlin, Germany
来源：
VALUE IN HEALTH | 2017年 / 20卷 / 09期
关键词：
D O I：
10.1016/j.jval.2017.08.757
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PMS36
引用
收藏
页码：A532 / A532
页数：1
相关论文
共 50 条
  • [31] Prevalence of psoriasis and psoriatic arthritis in Germany - analysis of claims data
    Hagenstroem, Kristina
    Mueller, Katharina
    Garbe, Claudia
    Augustin, Matthias
    [J]. JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2024, 22 (01): : 45 - 55
  • [32] A CLAIMS DATA ANALYSIS OF BIOLOGICAL AGENTS FOR PSORIATIC ARTHRITIS IN GERMANY
    Vollmer, L.
    Schleich, W.
    Rex, J.
    Walzer, S.
    [J]. VALUE IN HEALTH, 2017, 20 (09) : A532 - A532
  • [33] Biologics or tofacitinib for people with rheumatoid arthritis unsuccessfully treated with biologics: a systematic review and networkmeta-analysis
    Singh, Jasvinder A.
    Hossain, Alomgir
    Ghogomu, Elizabeth Tanjong
    Mudano, Amy S.
    Maxwell, Lara J.
    Buchbinder, Rachelle
    Lopez-Olivo, Maria Angeles
    Suarez-Almazor, Maria E.
    Tugwell, Peter
    Wells, George A.
    [J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2017, (03):
  • [34] RISK OF HOSPITALIZED INFECTIONS IN PATIENTS WITH RHEUMATOID ARTHRITIS INITIATING ABATACEPT AND OTHER BIOLOGICS: ANALYSIS OF A UNITED STATES CLAIMS DATABASE
    Baker, N.
    Boers, M.
    Hochberg, M.
    Kawabata, H.
    Ray, N.
    Simon, T.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 516 - 516
  • [35] Access to Biologics in rheumatoid Arthritis in Germany 2001-2012
    Pattloch, D.
    Manger, B.
    Klopsch, T.
    Meier, L.
    Tony, H.
    Zink, A.
    Strangfeld, A.
    [J]. ZEITSCHRIFT FUR RHEUMATOLOGIE, 2013, 72 : 53 - 54
  • [36] Treatment Patterns, Direct Cost of Biologics, and Direct Medical Costs for Rheumatoid Arthritis Patients: A Real-world Analysis of Nationwide Japanese Claims Data
    Sugiyama, Naonobu
    Kawahito, Yutaka
    Fujii, Takao
    Atsumi, Tatsuya
    Murata, Tatsunori
    Morishima, Yosuke
    Fukuma, Yuri
    [J]. CLINICAL THERAPEUTICS, 2016, 38 (06) : 1359 - 1375
  • [37] Real-world treatment persistence in patients with rheumatoid arthritis initiating DMARDs in Germany-a health insurance claims data analysis
    Fiehn, Christoph
    Zinke, Silke
    Haas, Jennifer S.
    Meise, Dominic
    Theil, Julia
    Gurrath, Margot
    Orzechowski, Hans-Dieter
    [J]. ZEITSCHRIFT FUR RHEUMATOLOGIE, 2023, 82 (09): : 739 - 753
  • [38] Cancer Incidence in Patients with Rheumatoid Arthritis Based on a Claims Database
    Wu, Chuntao
    Kurzinger, Marie-Laure
    Kumar, Meera
    Garg, Anju
    Lin, Stephen
    Juhaeri, Juhaeri
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2017, 26 : 73 - 74
  • [39] Comparison of the outcomes of Pneumocystis jirovecii pneumonia in rheumatoid arthritis patients treated with and without biologics
    Ohmura, Shin-ichiro
    Matsui, Hiroki
    Miyamoto, Toshiaki
    Shichi, Daisuke
    Masui, Takayuki
    Ichijo, Katsutoshi
    Homma, Yuya
    Fujioka, Haruka
    Nagai, Tatsuya
    Nakashima, Kei
    [J]. RESPIRATORY INVESTIGATION, 2024, 62 (03) : 377 - 383
  • [40] RHEUMATOID ARTHRITIS (RA) TREATMENT COSTS AMONG US PATIENTS TREATED WITH INFUSED BIOLOGICS
    Ogale, S.
    Henk, H. J.
    [J]. VALUE IN HEALTH, 2010, 13 (03) : A125 - A126
12345